The Emerging COVID-19 Therapy Market for Early Onset, Non-Hospitalized Patients: Three Segments to Watch

Three parallel worlds, segmented by socioeconomics, culture, and politics unfold during this pandemic, divided into what can be considered tier 1, tier 2, and tier 3 markets, where the former are the counties with the biggest economies, followed by the middle-tier developed or rapidly growing developing nations, followed finally by the latter lower-income nations. The stakes are large for the COVID-19 market for therapies treating early-onset, mild-to-moderate COVID-19, which is approximately 90% of incidents. Tier 1 counties’ demands for early-onset, mild-to-moderate COVID-19 therapy will be fulfilled by novel therapeutics developed by pharmaceutical companies, thanks in part to a confluence of forces that have successfully blocked the entrance of imminent low-cost options; while tier 2 will, in reality, reflect a mix of branded therapies localized in price and manufacturer along with moderately priced to low-cost generics with tier 3 overwhelmingly dependent on low-cost generic drugs such as ivermectin. Ivermectin’s mounting efficacy as exhibited in over 50 clinical trials, reveals increasing impact in places from Mexico City to Zimbabwe to India’s Uttar Pradesh state. But other repurposed generics show considerable promise from fluvoxamine to favipiravir and even hydroxychloroquine to indigenously developed drugs, such as one announced recently by the Indian ministry of defense. What follows is a breakdown of the important global market for early-onset, mild-to-moderate COVID-19 therapies and treatments.

Continue Reading Here



Submit a Comment